Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
EMERYVILLE, Calif., May 02, 2018 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences:
- Gregory T. Went, Ph.D., the company’s Founder, Chairman and Chief Executive Officer, is scheduled to present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 2:50 p.m. EDT
- Richard A. King, the company’s Chief Operating Officer, is scheduled to present at the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018 at 1:40 p.m. PDT
The presentations will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. Archived versions of the webcasts will be available via replay for 30 days following the presentations.
About Adamas Pharmaceuticals, Inc.
Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. The company is focused on the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and delivering on its pipeline of differentiated investigational programs. Those programs include: ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.
Contact:
Investors:
Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567
[email protected]
Media:
Terri Clevenger
Continuum Health Communications
203-227-0209
[email protected]
